AR095368A1 - Células madre mesenquimáticas primarias inmunoprotectoras y métodos para el tratamiento o prevención de una infección causada por un patógeno - Google Patents
Células madre mesenquimáticas primarias inmunoprotectoras y métodos para el tratamiento o prevención de una infección causada por un patógenoInfo
- Publication number
- AR095368A1 AR095368A1 ARP140100907A ARP140100907A AR095368A1 AR 095368 A1 AR095368 A1 AR 095368A1 AR P140100907 A ARP140100907 A AR P140100907A AR P140100907 A ARP140100907 A AR P140100907A AR 095368 A1 AR095368 A1 AR 095368A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibodies
- pathogen
- mesenchimatic
- immunoprotectorary
- prevention
- Prior art date
Links
- 208000015181 infectious disease Diseases 0.000 title abstract 2
- 244000052769 pathogen Species 0.000 title abstract 2
- 230000001717 pathogenic effect Effects 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title 1
- 210000000130 stem cell Anatomy 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 241000894006 Bacteria Species 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 101150007193 IFNB1 gene Proteins 0.000 abstract 1
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 108010065805 Interleukin-12 Proteins 0.000 abstract 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- 108090000978 Interleukin-4 Proteins 0.000 abstract 1
- 108090001005 Interleukin-6 Proteins 0.000 abstract 1
- 108010002586 Interleukin-7 Proteins 0.000 abstract 1
- 108010002335 Interleukin-9 Proteins 0.000 abstract 1
- 108010063738 Interleukins Proteins 0.000 abstract 1
- 102000015696 Interleukins Human genes 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 230000002480 immunoprotective effect Effects 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 abstract 1
- 244000045947 parasite Species 0.000 abstract 1
- 241000894007 species Species 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
Abstract
Se describen aquí células madre mesenquimáticas primarias inmunoprotectoras (IP-MSC) que episomalmente expresan múltiples polipéptidos inmunorreactivos que apuntan específicamente a un patógeno (por ejemplo, especies infecciosas de un virus, una bacteria, o un parásito) o toxina. El IP-MSC expresan dos o más (por ejemplo, aproximadamente 2 a 100) polipéptidos inmunorreactivos (por ejemplo, anticuerpos completos, anticuerpos de cadena única (scFv), Fab o F(ab)₂ de anticuerpos, anticuerpos de cadena doble, anticuerpos de cadena triple, y similares), y opcionalmente uno o más de otros polipéptidos inmunomoduladores, por ejemplo, una citoquina tal como una interleuquina (por ejemplo, IL-2, IL-4, IL-6, IL-7, IL-9 e IL-12), un interferón (por ejemplo, IFNa, IFNb o IFNw), y similares, que pueden mejorar la efectividad de los polipéptidos inmunorreactivos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/826,285 US9101597B2 (en) | 2013-03-14 | 2013-03-14 | Immunoprotective primary mesenchymal stem cells and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR095368A1 true AR095368A1 (es) | 2015-10-14 |
Family
ID=51527936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140100907A AR095368A1 (es) | 2013-03-14 | 2014-03-12 | Células madre mesenquimáticas primarias inmunoprotectoras y métodos para el tratamiento o prevención de una infección causada por un patógeno |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US9101597B2 (es) |
| EP (1) | EP2968611B1 (es) |
| JP (1) | JP6566932B2 (es) |
| CN (1) | CN105188768B (es) |
| AR (1) | AR095368A1 (es) |
| AU (1) | AU2014244057B2 (es) |
| CA (1) | CA2906592C (es) |
| EA (1) | EA201591673A1 (es) |
| ES (1) | ES2881383T3 (es) |
| HK (1) | HK1219050A1 (es) |
| MX (3) | MX366419B (es) |
| TW (2) | TWI650420B (es) |
| WO (1) | WO2014160157A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9101597B2 (en) * | 2013-03-14 | 2015-08-11 | The Administration Of The Tulane Educational Fund | Immunoprotective primary mesenchymal stem cells and methods |
| US11357866B2 (en) * | 2013-04-03 | 2022-06-14 | The Administrators Of The Tulane Educational Fund | Expression of HIV inhibitors by mesenchymal stem cells |
| US20170239297A1 (en) | 2014-08-18 | 2017-08-24 | Apceth Gmbh & Co. Kg | Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells |
| WO2016196740A1 (en) * | 2015-06-02 | 2016-12-08 | The Rockefeller University | Tri-specific antibodies for hiv therapy |
| KR20180105705A (ko) | 2016-02-04 | 2018-09-28 | 롱에버론 엘엘씨 | 백신 보조제로서의 중간엽 줄기 세포 및 그의 사용 방법 |
| AU2017277499B2 (en) * | 2016-06-07 | 2022-07-28 | The Pacific Heart, lung & Blood Institute | Compositions and methods for treating cancer |
| US11198723B2 (en) | 2016-12-05 | 2021-12-14 | The Administrators Of The Tulane Educational Fund | Arenavirus monoclonal antibodies and uses |
| US11118196B2 (en) * | 2019-09-05 | 2021-09-14 | Crispr Therapeutics Ag | Universal donor cells |
| CN111363045B (zh) * | 2020-02-18 | 2021-12-17 | 厦门大学 | 一种流感、hiv嵌合蛋白及嵌合病毒疫苗的制备方法 |
| US20230105667A1 (en) * | 2020-03-12 | 2023-04-06 | Exostem Biotec Ltd. | Mesenchymal stromal cells and extracellular vesicles for treating viral infections, inflammation, and tissue fibrosis |
| EP3881853A1 (en) * | 2020-03-20 | 2021-09-22 | Promethera Therapeutics Sa | Human allogeneic liver-derived progenitor cells for use in the treatment of inflammatory and infectious lung diseases and systemic inflammation |
| US20210299246A1 (en) * | 2020-03-27 | 2021-09-30 | R. Brannon Claytor | Methods and compositions for therapeutic treatment of viral or virally-induced infections and conditions, and anti-viral compositions and their production |
| US11566230B2 (en) | 2020-12-31 | 2023-01-31 | Crispr Therapeutics Ag | Universal donor cells |
| CN117323411B (zh) * | 2023-11-02 | 2024-08-06 | 徐州医科大学附属医院 | 破伤风类毒素在脐带干细胞损伤治疗中的应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040039186A1 (en) * | 1997-02-28 | 2004-02-26 | Boehringer Ingelheim Pharmaceuticals, Inc. | Self-regulated apoptosis of inflammatory cells by gene therapy |
| US6149906A (en) | 1997-09-20 | 2000-11-21 | Osiris Therapeutics, Inc. | Antigen presenting cells of the adipocyte lineage |
| JP2005510201A (ja) | 2001-01-26 | 2005-04-21 | アブジェニックス インコーポレイテッド | Ｈｉｖ−１に対する中和ヒトモノクローナル抗体、それらの産生および使用 |
| US20070196365A1 (en) * | 2001-02-20 | 2007-08-23 | Dov Zipori | Immunoglobulin heavy chain variants expressed in mesenchymal cells and therapeutic uses thereof |
| CA2484050A1 (en) * | 2001-09-20 | 2003-03-27 | Centre For Translational Research In Cancer | Cultured stromal cells and uses thereof |
| WO2005094846A1 (ja) * | 2004-03-30 | 2005-10-13 | Renomedix Institute Inc. | プリオン病治療剤およびその製造方法 |
| CN101166546A (zh) * | 2005-01-21 | 2008-04-23 | 因特罗根治疗公司 | 允许靶细胞长期暴露于治疗性和预防性核酸的局部施用 |
| US8076102B2 (en) | 2005-05-18 | 2011-12-13 | Biofactura, Inc. | Compositions and methods for metabolic selection of transfected cells |
| CN1872344A (zh) * | 2005-06-01 | 2006-12-06 | 上海二医新生基因科技有限公司 | 人异体间质干细胞（携带治疗基因）的基因治疗方法 |
| AU2007249160B2 (en) | 2006-05-15 | 2013-09-12 | I2 Pharmaceuticals, Inc. | Neutralizing antibodies to influenza viruses |
| EP1995309A1 (en) | 2007-05-21 | 2008-11-26 | Vivalis | Recombinant protein production in avian EBx® cells |
| JP5773366B2 (ja) * | 2008-04-21 | 2015-09-02 | ティシュー リジェネレイション セラピューティックス、インコーポレイテッド | 生物学的又は化学的作用物質に対する予防又はそれらの治療のために遺伝子改変されたヒト臍帯血管周囲細胞 |
| US9707322B2 (en) * | 2012-12-21 | 2017-07-18 | University Of Connecticut | Gradient porous scaffolds |
| US10472647B2 (en) * | 2012-12-21 | 2019-11-12 | The Administrators Of The Tulane Educational Fund | Primary mesenchymal stem cells as a vaccine platform |
| US9101597B2 (en) * | 2013-03-14 | 2015-08-11 | The Administration Of The Tulane Educational Fund | Immunoprotective primary mesenchymal stem cells and methods |
-
2013
- 2013-03-14 US US13/826,285 patent/US9101597B2/en active Active
-
2014
- 2014-03-12 AR ARP140100907A patent/AR095368A1/es unknown
- 2014-03-13 ES ES14774631T patent/ES2881383T3/es active Active
- 2014-03-13 WO PCT/US2014/025941 patent/WO2014160157A1/en active Application Filing
- 2014-03-13 MX MX2015013387A patent/MX366419B/es active IP Right Grant
- 2014-03-13 MX MX2019000704A patent/MX2019000704A/es unknown
- 2014-03-13 EP EP14774631.7A patent/EP2968611B1/en active Active
- 2014-03-13 CA CA2906592A patent/CA2906592C/en active Active
- 2014-03-13 AU AU2014244057A patent/AU2014244057B2/en active Active
- 2014-03-13 JP JP2016502003A patent/JP6566932B2/ja active Active
- 2014-03-13 TW TW103109173A patent/TWI650420B/zh active
- 2014-03-13 EA EA201591673A patent/EA201591673A1/ru unknown
- 2014-03-13 CN CN201480026798.5A patent/CN105188768B/zh active Active
- 2014-03-13 TW TW107138753A patent/TWI689590B/zh active
-
2015
- 2015-07-17 US US14/802,247 patent/US10357562B2/en active Active
- 2015-09-14 MX MX2019008195A patent/MX2019008195A/es unknown
-
2016
- 2016-06-21 HK HK16107097.9A patent/HK1219050A1/zh unknown
-
2019
- 2019-05-30 US US16/426,911 patent/US11123427B2/en active Active
-
2021
- 2021-09-17 US US17/477,725 patent/US20210401984A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TWI650420B (zh) | 2019-02-11 |
| US10357562B2 (en) | 2019-07-23 |
| HK1219050A1 (zh) | 2017-03-24 |
| TWI689590B (zh) | 2020-04-01 |
| US9101597B2 (en) | 2015-08-11 |
| EP2968611B1 (en) | 2021-05-05 |
| CA2906592C (en) | 2022-01-18 |
| EP2968611A4 (en) | 2016-08-17 |
| CN105188768A (zh) | 2015-12-23 |
| MX2019000704A (es) | 2020-11-12 |
| MX2015013387A (es) | 2016-08-11 |
| EA201591673A1 (ru) | 2016-01-29 |
| EP2968611A1 (en) | 2016-01-20 |
| CN105188768B (zh) | 2019-06-28 |
| ES2881383T3 (es) | 2021-11-29 |
| TW201907005A (zh) | 2019-02-16 |
| WO2014160157A1 (en) | 2014-10-02 |
| US11123427B2 (en) | 2021-09-21 |
| AU2014244057A1 (en) | 2015-10-29 |
| MX2019008195A (es) | 2019-09-11 |
| AU2014244057B2 (en) | 2018-12-06 |
| US20160129110A1 (en) | 2016-05-12 |
| MX366419B (es) | 2019-07-08 |
| TW201514301A (zh) | 2015-04-16 |
| US20190282694A1 (en) | 2019-09-19 |
| US20140271580A1 (en) | 2014-09-18 |
| JP6566932B2 (ja) | 2019-08-28 |
| CA2906592A1 (en) | 2014-10-02 |
| US20210401984A1 (en) | 2021-12-30 |
| JP2016518819A (ja) | 2016-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR095368A1 (es) | Células madre mesenquimáticas primarias inmunoprotectoras y métodos para el tratamiento o prevención de una infección causada por un patógeno | |
| CO2020001828A2 (es) | Conjugados de citoquina para el tratamiento de enfermedades proliferativas e infecciosas | |
| MX2023013140A (es) | Vacunas contra el virus de la hepatitis b. | |
| BR112018010430A2 (pt) | composições bacterianas projetadas | |
| EA201990566A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| CL2021001352A1 (es) | Composiciones a base de levadura para mejorar las propiedades de la rizosfera y la salud de las plantas | |
| MX2018008413A (es) | Virus oncolitico modificado. | |
| EA201692303A1 (ru) | Новая противоинфекционная стратегия против коинфекций, вызванных вирусом гриппа и s.aureus | |
| TR201820333T4 (tr) | Bakteri Suşları İçeren Bileşimler | |
| EA030115B9 (ru) | Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b | |
| EA201891202A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| EA201890945A1 (ru) | Биологические препараты и их применение в отношении растений | |
| EA201890049A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| NZ730809A (en) | Methods for treating filoviridae virus infections | |
| GT201200249A (es) | Cepa bacteriana aislada del genero burkholderia y metabolitos pesticidas del mismo | |
| CL2012002782A1 (es) | Compuestos derivados de pirazol-4-il-heterociclil-carboxamida, inhibidores de los trastornos mediados por las quinasas pim-1, pim-2 y pim-3; composición farmacéutica; mètodo de tratamiento; y su uso para el tratamiento del càncer, trastornos inmunes, enfermedades cardiovasculares e infecciones virales , entre otros. | |
| CY1125211T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
| WO2016210384A3 (en) | Bacteria engineered to treat metabolic diseases | |
| NZ727392A (en) | Methods of preparing substituted nucleotide analogs | |
| CL2020003442A1 (es) | Tiofenocarboxamidas sustituidas y análogos de las mismas | |
| PH12016501999A1 (en) | Novel bacteriophage and composition containing same | |
| EA201790517A1 (ru) | Способы и композиции для индуцирования защитного иммунитета против филовирусной инфекции | |
| MX2022016066A (es) | Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas. | |
| EA201891555A1 (ru) | Вирус вакцины от репродуктивно-респираторного синдрома свиней | |
| PH12018502672A1 (en) | Method for increasing nitrogen-use efficiency and or nitrogen-utilisation efficiency in plants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |